Private Advisor Group LLC Sells 8,343 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Private Advisor Group LLC reduced its position in shares of Elanco Animal Health Incorporated (NYSE:ELANFree Report) by 5.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 139,744 shares of the company’s stock after selling 8,343 shares during the quarter. Private Advisor Group LLC’s holdings in Elanco Animal Health were worth $2,275,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Principal Financial Group Inc. lifted its stake in shares of Elanco Animal Health by 55.0% in the 1st quarter. Principal Financial Group Inc. now owns 139,543 shares of the company’s stock valued at $2,272,000 after purchasing an additional 49,497 shares during the period. Mitchell & Pahl Private Wealth LLC increased its holdings in Elanco Animal Health by 8.5% in the first quarter. Mitchell & Pahl Private Wealth LLC now owns 36,528 shares of the company’s stock valued at $595,000 after purchasing an additional 2,871 shares during the last quarter. Bfsg LLC lifted its stake in Elanco Animal Health by 8.2% in the first quarter. Bfsg LLC now owns 14,885 shares of the company’s stock valued at $242,000 after buying an additional 1,125 shares during the period. Wesbanco Bank Inc. bought a new position in Elanco Animal Health during the first quarter worth about $2,437,000. Finally, Raymond James Financial Services Advisors Inc. grew its position in shares of Elanco Animal Health by 5.2% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 267,907 shares of the company’s stock worth $4,362,000 after buying an additional 13,218 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Trading Down 1.9 %

Shares of NYSE:ELAN opened at $13.95 on Tuesday. The firm has a market cap of $6.89 billion, a price-to-earnings ratio of -5.26, a PEG ratio of 1.38 and a beta of 1.42. Elanco Animal Health Incorporated has a 12 month low of $8.52 and a 12 month high of $18.80. The company’s fifty day simple moving average is $16.53 and its 200 day simple moving average is $15.72. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.95.

Elanco Animal Health (NYSE:ELANGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.08. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The company’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter last year, the business posted $0.45 EPS. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 0.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Barclays reduced their price objective on shares of Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Friday, June 28th. Piper Sandler reduced their price target on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Monday, July 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.57.

View Our Latest Research Report on ELAN

Insiders Place Their Bets

In other Elanco Animal Health news, Director William F. Doyle acquired 15,000 shares of the business’s stock in a transaction dated Tuesday, May 21st. The shares were acquired at an average price of $16.98 per share, with a total value of $254,700.00. Following the completion of the transaction, the director now directly owns 76,330 shares in the company, valued at approximately $1,296,083.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.57% of the company’s stock.

Elanco Animal Health Company Profile

(Free Report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

See Also

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.